| Item type |
文献 / Documents(1) |
| 公開日 |
2024-10-18 |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| item_1722929371688 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1038/sj.bjc.6606029 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1038/sj.bjc.6606029 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma |
|
言語 |
en |
| タイトル別表記 |
|
|
その他のタイトル |
Sunitinib-induced thyroid atrophy in metastatic RCC |
|
言語 |
en |
| 著者 |
Shinohara, N
高橋, 正幸
Kamishima, T
生島, 仁史
Otsuka, N
Ishizu, A
Shimizu, C
金山, 博臣
Nonomura, K
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
BACKGROUND: To elucidate the incidence and mechanisms of sunitinib-induced thyroid atrophy, we investigated serial volumetric and functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received sunitinib.
METHODS: Thyroid volume (by computed tomography volumetry) and thyroid function were measured at baseline, during the treatment, and at post-treatment periods. Histological evaluation of the thyroid gland was performed in four autopsied patients.
RESULTS: The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n=8; more than 50% reduction in volume) than in the low reduction rate group (n=9; less than 50% reduction in volume). Half of the patients in the high reduction rate group exhibited a transient thyroid-stimulating hormone suppression, suggesting thyrotoxicosis during sunitinib treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without critical diminution of vascular volume in the thyroid gland.
CONCLUSION: Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-induced thyrotoxicosis or the direct effects of sunitinib that lead to degeneration of thyroid follicular cells. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
thyroid atrophy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hypothyroidism |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
sunitinib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
renal cell carcinoma |
| bibliographic_information |
en : British Journal of Cancer
巻 104,
号 2,
p. 241-247,
発行日 2010-12-04
|
| 収録物ID |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
15321827 |
| 収録物ID |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
00070920 |
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| item_10001_rights_15 |
|
|
言語 |
en |
|
権利情報 |
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. |
| item_1723180141928 |
|
|
識別子 |
252700 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
bjc_104_2_241.pdf (1010 KB)
.png)
